FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200529384> ?p ?o ?g. }

• W3200529384 endingPage "397" @default.
• W3200529384 startingPage "385" @default.
• W3200529384 abstract "Fabry disease, an X-linked lysosomal storage disorder characterized by absent or reduced alpha-galactosidase activity, is a lifelong disease that impairs patients' quality of life. Patients with Fabry disease have a considerably shortened lifespan, with mortality being mainly due to renal failure, cardiovascular disease, or cerebrovascular disease. Enzyme replacement therapy with agalsidase alfa has been shown to attenuate the renal, cardiovascular, and neuropathic disease progression associated with Fabry disease. The objective of this study was to investigate the safety of a new animal component-free version of agalsidase alfa.A phase III/IV, open-label, single-arm, multicenter safety study was conducted in Canadian patients with Fabry disease between August 2011 and September 2017 as a regulatory requirement to assess the safety of agalsidase alfa produced using an animal component-free bioreactor process. Eligible patients had a documented diagnosis of Fabry disease and satisfied current Canadian guidelines for receiving enzyme replacement therapy for Fabry disease. Following treatment with animal component-free bioreactor-processed agalsidase alfa, treatment-emergent adverse events were monitored, and post hoc analyses of infusion-related reactions by antidrug antibody and neutralizing antibody statuses were conducted. The data were analyzed using descriptive statistics.A total of 167 patients (mean [standard deviation] age, 48.9 [14.8] years), including six pediatric patients (< 18 years of age), received at least one full or partial infusion of agalsidase alfa animal component-free. Fewer than 5% of treatment-emergent adverse events (212/4446) observed in 40 patients were reported as infusion-related reactions. Antidrug antibody and neutralizing antibody status did not affect the proportion of patients with infusion-related reactions. No clinically significant changes in vital signs were observed in patients over the course of the study.Long-term treatment with bioreactor-produced agalsidase alfa animal component-free did not reveal new safety signals in this population of Canadian patients with Fabry disease. The treatment-emergent adverse event profile was consistent with the clinical manifestations of the disease and the known safety profile of roller bottle-produced agalsidase alfa.ClinicalTrials.gov identifier NCT01298141." @default.
• W3200529384 created "2021-09-27" @default.
• W3200529384 creator A5001052872 @default.
• W3200529384 creator A5017390306 @default.
• W3200529384 creator A5045675504 @default.
• W3200529384 creator A5063457276 @default.
• W3200529384 creator A5074710743 @default.
• W3200529384 creator A5081013431 @default.
• W3200529384 creator A5082014716 @default.
• W3200529384 date "2021-09-20" @default.
• W3200529384 modified "2023-10-08" @default.
• W3200529384 title "The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process" @default.
• W3200529384 cites W1530794397 @default.
• W3200529384 cites W1545472958 @default.
• W3200529384 cites W1805405386 @default.
• W3200529384 cites W1964199934 @default.
• W3200529384 cites W1984896762 @default.
• W3200529384 cites W1989174499 @default.
• W3200529384 cites W1989708725 @default.
• W3200529384 cites W2000351355 @default.
• W3200529384 cites W2007517041 @default.
• W3200529384 cites W2022356406 @default.
• W3200529384 cites W2034306630 @default.
• W3200529384 cites W2069483072 @default.
• W3200529384 cites W2108139865 @default.
• W3200529384 cites W2139927163 @default.
• W3200529384 cites W2146877343 @default.
• W3200529384 cites W2153471521 @default.
• W3200529384 cites W2156219519 @default.
• W3200529384 cites W2160213856 @default.
• W3200529384 cites W2163242168 @default.
• W3200529384 cites W2165008949 @default.
• W3200529384 cites W237868679 @default.
• W3200529384 cites W2396040387 @default.
• W3200529384 cites W2566128997 @default.
• W3200529384 cites W2622073506 @default.
• W3200529384 cites W2756545627 @default.
• W3200529384 cites W2789753965 @default.
• W3200529384 cites W2893439500 @default.
• W3200529384 cites W2918101713 @default.
• W3200529384 cites W4211146209 @default.
• W3200529384 doi "https://doi.org/10.1007/s40268-021-00361-4" @default.
• W3200529384 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8602602" @default.
• W3200529384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34542871" @default.
• W3200529384 hasPublicationYear "2021" @default.
• W3200529384 type Work @default.
• W3200529384 sameAs 3200529384 @default.
• W3200529384 citedByCount "1" @default.
• W3200529384 countsByYear W32005293842023 @default.
• W3200529384 crossrefType "journal-article" @default.
• W3200529384 hasAuthorship W3200529384A5001052872 @default.
• W3200529384 hasAuthorship W3200529384A5017390306 @default.
• W3200529384 hasAuthorship W3200529384A5045675504 @default.
• W3200529384 hasAuthorship W3200529384A5063457276 @default.
• W3200529384 hasAuthorship W3200529384A5074710743 @default.
• W3200529384 hasAuthorship W3200529384A5081013431 @default.
• W3200529384 hasAuthorship W3200529384A5082014716 @default.
• W3200529384 hasBestOaLocation W32005293841 @default.
• W3200529384 hasConcept C126322002 @default.
• W3200529384 hasConcept C197934379 @default.
• W3200529384 hasConcept C2777404818 @default.
• W3200529384 hasConcept C2779134260 @default.
• W3200529384 hasConcept C2779969927 @default.
• W3200529384 hasConcept C71924100 @default.
• W3200529384 hasConceptScore W3200529384C126322002 @default.
• W3200529384 hasConceptScore W3200529384C197934379 @default.
• W3200529384 hasConceptScore W3200529384C2777404818 @default.
• W3200529384 hasConceptScore W3200529384C2779134260 @default.
• W3200529384 hasConceptScore W3200529384C2779969927 @default.
• W3200529384 hasConceptScore W3200529384C71924100 @default.
• W3200529384 hasIssue "4" @default.
• W3200529384 hasLocation W32005293841 @default.
• W3200529384 hasLocation W32005293842 @default.
• W3200529384 hasLocation W32005293843 @default.
• W3200529384 hasOpenAccess W3200529384 @default.
• W3200529384 hasPrimaryLocation W32005293841 @default.
• W3200529384 hasRelatedWork W101106520 @default.
• W3200529384 hasRelatedWork W1569134475 @default.
• W3200529384 hasRelatedWork W1983441358 @default.
• W3200529384 hasRelatedWork W2016175017 @default.
• W3200529384 hasRelatedWork W2030708032 @default.
• W3200529384 hasRelatedWork W2043774580 @default.
• W3200529384 hasRelatedWork W2137567062 @default.
• W3200529384 hasRelatedWork W2150288618 @default.
• W3200529384 hasRelatedWork W2409848207 @default.
• W3200529384 hasRelatedWork W2461089968 @default.
• W3200529384 hasVolume "21" @default.
• W3200529384 isParatext "false" @default.
• W3200529384 isRetracted "false" @default.
• W3200529384 magId "3200529384" @default.
• W3200529384 workType "article" @default.